Featured News

The ACeD Study is looking for volunteers with celiac disease to participate in a phase 1 clinical trial testing the investigational drug KAN-101.

We are pleased to share that CEO Marilyn Geller will be presenting as the Patient Advocate at the March 18-19 National Institute of Allergy and Infectious Diseases Accelerating Progress in Celiac Disease Workshop. We encourage you to register to attend this seminal virtual meeting.

Rep. Betty McCollum (D-MN) and Rep. Steve Stivers (D-OH) announced the formation of the Congressional Celiac Disease Caucus at the 2021 Celiac Disease Foundation Patient Education & Advocacy Summit.

Hear from the Foundation’s CEO, Marilyn G. Geller, on today’s episode of the Celiac Project Podcast! Learn all about our groundbreaking Patient Education and Advocacy Summit, the monumental ways CDF is helping to advance legislation and research for celiac disease.

The Celiac Disease Genomic Environmental Microbiome and Metabolomic (CDGEMM) study is revealing how genetic and lifestyle factors make children susceptible to autoimmune diseases such as celiac disease, inflammatory bowel disease, and multiple sclerosis.

Thank you to Labcorp for sponsoring our upcoming Patient Education and Advocacy Summit. Labcorp is a global life sciences company that brings diagnostic testing and drug development together. Register now!

Thank you to Takeda for sponsoring our upcoming Patient Education and Advocacy Summit. With nearly 30 years of experience in gastroenterology, Takeda has made significant strides toward closing the gap on unmet needs for patients who have celiac disease. Register now to be a part of this momentous event

Thank you to 9 Meters for sponsoring our upcoming Patient Education and Advocacy Summit. 9 Meters is a gastroenterology-focused therapeutics company targeting GI diseases with unmet needs. Register now! Celiac.org/summit

Thank you to Provention Bio, Inc., for supporting our upcoming Patient Education and Advocacy Summit. Provention Bio, Inc., is a clinical-stage biopharmaceutical company developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases. Register now

With your help, we have invested significant resources into changing that reality in Washington, DC, and we are beginning to see a return on that investment.